{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T19:52:29Z","timestamp":1794426749492,"version":"4.9.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T00:00:00Z","timestamp":1731801600000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ygyno.2023.10.017","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T17:28:10Z","timestamp":1700242090000},"page":"115-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement"],"prefix":"10.1016","volume":"179","author":[{"given":"Eugenia","family":"Girda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie M.","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Chino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Farley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin E.","family":"O'Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2023.10.017_bb0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0010","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.meegid.2018.03.003","article-title":"Understanding the HPV integration and its progression to cervical cancer","volume":"61","author":"Oyervides-Munoz","year":"2018","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/ng.3178","article-title":"Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism","volume":"47","author":"Hu","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0025","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","author":"Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, Barretos Cancer Hospital, Baylor College of Medicine, Beckman Research Institute of City of Hope, et al","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0030","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/ijc.21461","article-title":"Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation","volume":"118","author":"Bertelsen","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022769","article-title":"PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers","volume":"6","author":"Janku","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0040","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ygyno.2012.12.019","article-title":"PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy","volume":"128","author":"McIntyre","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0045","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1158\/1078-0432.CCR-14-1837","article-title":"Genome analysis of Latin American cervical cancer: frequent activation of the PIK3CA pathway","volume":"21","author":"Lou","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0050","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/sj.bjc.6603180","article-title":"Increased expression of pAKT is associated with radiation resistance in cervical cancer","volume":"94","author":"Kim","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0055","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1158\/0008-5472.CAN-07-6656","article-title":"Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance","volume":"69","author":"Ihle","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2011.36.1196","article-title":"PI3K\/AKT\/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations","volume":"30","author":"Janku","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0065","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2018.29.e4","article-title":"Mutational analysis of KRAS and its clinical implications in cervical cancer patients","volume":"29","author":"Jiang","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0070","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3892\/ol.2017.6435","article-title":"Mutational analysis of the RAS\/RAF\/MEK\/ERK signaling pathway in 260 Han Chinese patients with cervical carcinoma","volume":"14","author":"Zou","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ygyno.2019.05.003","article-title":"Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer","volume":"154","author":"Liu","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0080","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.ijrobp.2015.03.010","article-title":"Image-based brachytherapy for the treatment of cervical cancer","volume":"92","author":"Harkenrider","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0085","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1200\/JCO.22.01096","article-title":"Risk factors for local failure following chemoradiation and magnetic resonance image-guided brachytherapy in locally advanced cervical cancer: results from the EMBRACE-I study","volume":"41","author":"Schmid","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijrobp.2013.11.228","article-title":"Patterns of radiation therapy practice for patients treated for intact cervical cancer in 2005 to 2007: a quality research in radiation oncology study","volume":"89","author":"Eifel","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.16.00072","article-title":"Data-derived treatment duration goal for cervical cancer: should 8 weeks remain the target in the era of concurrent chemoradiation?","volume":"1","author":"Hong","year":"2017","journal-title":"JCO Clin. Cancer Inform."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0100","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.3390\/cancers15092571","article-title":"Racial disparities in brachytherapy treatment among women with cervical and endometrial cancer in the United States","volume":"15","author":"Taparra","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0105","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Cervical Cancer","year":"2023"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0110","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/1097-0142(19850501)55:9+<2123::AID-CNCR2820551415>3.0.CO;2-O","article-title":"Biological basis for the interaction of chemotherapeutic agents and radiation therapy","volume":"55","author":"Fu","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0115","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1200\/JCO.2009.25.9663","article-title":"Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix","volume":"29","author":"Duenas-Gonzalez","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"suppl 16","key":"10.1016\/j.ygyno.2023.10.017_bb0120","article-title":"Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: results from NRG-GY006, a phase III randomized trial","volume":"41","author":"Leath","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0125","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S1470-2045(23)00147-X","article-title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0130","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/ijgc-2019-001012","article-title":"Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer","volume":"30","author":"Mayadev","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0135","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/ijgc-2019-001135","article-title":"CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study","volume":"30","author":"Mayadev","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2023.10.017_bb0140","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS6096","article-title":"ENGOT-cx11\/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer","volume":"38","author":"Lorusso","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0145","unstructured":"C. Chargari, Trial assessing the inhibitor of programmed cell death ligand 1 (PD-L1) immune checkpoint atezolizumab (ATEZOLACC), ClinicalTrials.gov identifier: NCT03612791. Updated March 3, 2022. Accessed November 22, 2022. https:\/\/clinicaltrialsgov\/ct2\/show\/NCT03612791."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0150","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1136\/ijgc-2022-003370","article-title":"ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation","volume":"32","author":"Garcia-Duran","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0155","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0160","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0165","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0170","first-page":"S18","article-title":"Patient-reported outcomes from the phase 3 randomized, double-blind, KEYNOTE-826 trial of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (023), Gynecol.","volume":"166","author":"Monk","year":"2022","journal-title":"Oncol."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2023.10.017_bb0175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5594","volume":"37","author":"Oaknin","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0180","unstructured":"Y.N. Linkova, Efficacy and safety of BCD-100 (anti-PD-1) in combination with platinum-based chemotherapy with and without bevacizumab as first-line treatment of subjects with advanced cervical cancer (FERMATA), ClinicalTrials.gov identifier: NCT03912415. Updated September 18, 2020. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03912415"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0185","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ygyno.2012.09.008","article-title":"Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a Gynecologic Oncology Group study","volume":"127","author":"Alberts","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0190","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/COC.0b013e31803377c8","article-title":"Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"30","author":"Garcia","year":"2007","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0195","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00000421-199610000-00002","article-title":"A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"19","author":"Look","year":"1996","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0200","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ygyno.2004.09.027","article-title":"Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"96","author":"Schilder","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0205","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF00273403","article-title":"A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix","volume":"18","author":"Coleman","year":"1986","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0210","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO.1997.15.2.625","article-title":"Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix","volume":"15","author":"Verschraegen","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0215","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0959-8049(01)00178-2","article-title":"Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study","volume":"37","author":"Wagenaar","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2008.03.009","article-title":"Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"110","author":"Miller","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0225","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1006\/gyno.2000.5807","article-title":"Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"77","author":"Bookman","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0230","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1006\/gyno.2000.6024","article-title":"A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"81","author":"Muderspach","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0235","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ygyno.2003.10.045","article-title":"Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"92","author":"Muggia","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0240","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","article-title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0245","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ygyno.2003.11.019","article-title":"Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma","volume":"92","author":"Tiersten","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0250","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2011.06.001","article-title":"SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer","volume":"123","author":"Symonds","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0255","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0260","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0265","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II CheckMate 358 trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0270","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.21.02067","article-title":"Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0275","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0280","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ygyno.2007.09.019","article-title":"The impact of cervical cancer on quality of life\u2013the components and means for management","volume":"107","author":"Herzog","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0285","first-page":"3095","article-title":"Quality of life of patients with advanced cervical cancer before and after chemoradiotherapy","volume":"17","author":"Dahiya","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0290","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1590\/S0104-11692010000300010","article-title":"Health related quality of life of women with cervical cancer","volume":"18","author":"Fernandes","year":"2010","journal-title":"Rev. Lat. Am. Enfermagem"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0295","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1200\/JCO.2004.00.3996","article-title":"Quality of life and sexual functioning in cervical cancer survivors","volume":"23","author":"Frumovitz","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0300","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijrobp.2014.02.018","article-title":"Posttraumatic stress disorder after high-dose-rate brachytherapy for cervical cancer with 2 fractions in 1 application under spinal\/epidural anesthesia: incidence and risk factors","volume":"89","author":"Kirchheiner","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0305","article-title":"Opioid use in patients with cervical cancer at two urban medical centers","volume":"7","author":"Arya","year":"2022","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0310","first-page":"353","article-title":"Female erectile tissues and sexual dysfunction after pelvic radiotherapy: a scoping review","volume":"72","author":"Marshall","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0315","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/cncr.22719","article-title":"Use of health-related and cancer-specific support groups among adult cancer survivors","volume":"109","author":"Owen","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0320","first-page":"437","article-title":"Navigating financial toxicity in patients with cancer: a multidisciplinary management approach","volume":"72","author":"Smith","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0325","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2019.04.003","article-title":"Financial toxicity in gynecologic oncology","volume":"154","author":"Bouberhan","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0330","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.trecan.2021.12.007","article-title":"Role of financial toxicity in perpetuating health disparities","volume":"8","author":"Shah","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0335","doi-asserted-by":"crossref","first-page":"817.e1","DOI":"10.1016\/j.ajog.2021.12.012","article-title":"Risk factors for financial toxicity in patients with gynecologic cancer","volume":"226","author":"Aviki","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0340","doi-asserted-by":"crossref","first-page":"384.e1","DOI":"10.1016\/j.ajog.2021.09.034","article-title":"Catastrophic health expenditures, insurance churn, and nonemployment among gynecologic cancer patients in the United States","volume":"226","author":"Albright","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0345","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/OP.22.00085","article-title":"Systems-level changes to address financial toxicity in cancer care","volume":"18","author":"Giap","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0350","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ygyno.2022.03.031","article-title":"Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: a cost-effectiveness analysis","volume":"165","author":"Barrington","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0355","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.7863","article-title":"Oncologists\u2019 attitudes toward cancer care affordability","volume":"5","author":"Aviki","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0360","first-page":"2713","article-title":"Patient-reported benefit from proposed interventions to reduce financial toxicity during cancer treatment","volume":"30","author":"Aviki","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0365","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamaoncol.2020.1475","article-title":"Assessment of parking fees at national cancer institute-designated cancer treatment centers","volume":"6","author":"Lee","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2023.10.017_bb0370","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.2985","article-title":"Mediation of racial and ethnic inequities in the diagnosis of advanced-stage cervical cancer by insurance status","volume":"6","author":"Holt","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ygyno.2023.10.017_bb0375","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ygyno.2023.05.006","article-title":"Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: a joint statement from GOG Foundation and Society of Gynecologic Oncology (SGO)","volume":"174","author":"Pothuri","year":"2023","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582301510X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582301510X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:06:23Z","timestamp":1758773183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582301510X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":75,"alternative-id":["S009082582301510X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.10.017","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}